Amatuximab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed on many epithelial-derived cancer cells. Upon binding to the mesothelin antigen, amatuximab triggers an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing cells, resulting in cell lysis.

**Synonyms:** - AMATUXIMAB - Anti-Mesothelin Monoclonal Antibody MORAb-009 - Immunoglobulin G1, Anti-(mesothelin) (Human-Mouse Monoclonal MORAb-009 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-009 Kappa-Chain, Dimer - MORAb-009 - MORAb-009 - anti-mesothelin monoclonal antibody MORAb-009